Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma
(WorldNews Health)

- Opinion based on positive Phase 3 ALCANZA study results which demonstrated a highly statistically significant improvement in rate of objective response lasting at least four months,median progression-free survival and overall response rate, and decrease in symptom burden in ADCETRIS arm - Cambridge, Mass. and Osaka, Japan, November 14, 2017 - Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency`s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the marketing authorization of ADCETRIS® (brentuximab vedotin) and recommended its approval for the treatment of adult patients with...